As shown in Figure 2, the percentages of IFN-γ+Th1 cells, IL-17+Th17 cells, and circulating CD4+CCR7lowPD-1highTfh among CD4+T cells were lower in peripheral blood of RA patients after 52 weeks of therapy with iguratimod in group A. This effect was most pronounced for IFN-γ+Th1 cells. This evidence concerns the gene IL17A and rheumatoid arthritis.